Hans Bishop

Serial entrepreneur and a globally renowned leader in biotechnology

Hans is an Unreasonable Mentor. Hans was part of Unreasonable Impact UK 2017, and has advised over 11 Unreasonable companies.

Hans Bishop is currently the President, Founder, and Board Co-Chair of Altos Labs (their mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life). Hans served previously as the CEO of GRAIL, which was acquired by Illumina. From 2013 to 2018, he served as President and CEO at Juno Therapeutics, a company that he co-founded and that was acquired by Celgene. Juno was dedicated a company dedicated to curing diseases like cancer. Before Juno, Hans served as an Executive in Residence at Warburg Pincus. Earlier in his career, he was the Executive Vice President and Chief Operating Officer for Dendreon. Hans also previously served as President of Specialty Medicine at Bayer Healthcare and Senior Vice President of Global Commercial Operations at Chiron Corporation. He currently serves as the Chairman of Sana Biotechnology’s Board of Directors and held previous board roles at Agilent Technologies and Lyell Immunopharma.